Comparative Effectiveness of Risankizumab Versus Tumour Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve Patients With Psoriatic Arthritis: A Global Real-World Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2614; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • HEOR • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A
|